New Zealand diabetes cohort study cardiovascular risk score for people with Type 2 diabetes: Validation in the PREDICT cohort

Journal of Primary Health Care

Volumn 4, Issue 3, 2012, Pages 181-188

  Robinson, Tom ^a,b   Raina Elley, C ^a   Wells, Sue ^a   Robinson, Elizabeth ^a   Kenealy, Tim ^a   Pylypchuk, Romana ^a   Bramley, Dale ^b   Arroll, Bruce ^a   Crengle, Sue ^a   Riddell, Tania ^a   Ameratunga, Shanthi ^a   Metcalf, Patricia ^a   Drury, Paul L ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cardiovascular disease; Diabetes; Prevention; Reliability and validity; Risk assessment

Indexed keywords

EID: 84865844216     PISSN: 11726164     EISSN: 11726156     Source Type: Journal    
DOI: 10.1071/hc12181     Document Type: Article

References (24)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
3. Wright C. Estimated prevalence of Type 2 Diabetes in New Zealand. In: Robinson T, editor. Wellington: Ministry of Health; 2011.
4. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.
6. SIGN. Management of diabetes: a national clinical guideline: Scottish Intercollegiate Guidelines Network. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010.
7. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with Type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res. 2010;7(2):119-30.
8. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070-80.
9. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. New Eng J Med. 2008;359(15):1577-89.
11. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. New Eng J Med. 2008;359(15):1565-76.
12. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434-41.
13. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
14. New Zealand Guidelines Group. Evidence-based best-practice guideline. The assessment and managment of cardiovascular risk. Wellington: New Zealand Guidelines Group; 2003.
15. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: a summary resource for primary care practitioners. 2009 edition. Wellington: New Zealand Guidelines Group; 2009.
16. Anderson K, Odell P, Wilson P, Kannel W. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-8.
17. Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemo-globin and cardiovascular outcomes in people with Type2 diabetes: a large prospective cohort study. Diabet Med. 2008;25(11):1295-301.
18. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-31.
19. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care. 2004;27(3):704-8.
20. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess. 2005;9(30):3-6. 13-163.
21. Elley C, Robinson E, Kenealy T, Bramley D, Drury P. Derivation and validation of a new cardiovascular risk score for people with Type 2 diabetes: The New Zealand Diabetes Cohort Study. Diabetes Care. 2010;33(6):1347-52.
22. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.
23. Bannink L, Wells S, Broad J, Riddell T, Jackson R. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18000 patients (PREDICT CVD-1). N Z Med J. 2006;119(1245):U2313.
24. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med. 2008;168(21):2304-10.